The XIENCE™ DES is proven to offer unparalleled patient outcomes during and long after percutaneous coronary interventions (PCI).1 With over 20 million implants and studied in 120+ clinical trials,2 XIENCE™ Stent provides consistent long-term safety data out to 10 years.3 XIENCE™ Stent allows interventional cardiologists (ICs) to achieve the positive outcomes they want for their patients.
1-month DAPT indication for
High Bleeding Risk Patients
XIENCE Skypoint™ Drug Eluting Stent System
The latest DES in the XIENCE™ Family, XIENCE Skypoint™ Stent has an enhanced design that offers better expansion, excellent deliverability, expanded treatment options including a 48 mm design, and trusted patient outcomes.1,4
XIENCE Sierra™ Drug Eluting Stent System
XIENCE Sierra™ Stent has an enhanced design that offers deliverability, pushability, post dilatation expansion as well as an ultra-low profile and smoother crossing.4
References
- Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363(2):136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2012;379(9824);1393-1402. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6:378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet 2018;392:737-746. Data on file at Abbott.
- Data on file at Abbott – 12 million patients number is based on data of DES implants through Q2, 2022.
- Kufner S, et al. Circulation. 2019:139(3):325-333. Outcomes may not be representative of all patients. Shiomi H, et al. J Am Coll Cardiol Interv. 2019;12:637-647.
- XIENCE Skypoint™ Stent Instructions for Use (IFU). Refer to IFU for additional information. Data on file at Abbott. Benchtop testing may not be indicative of clinical performance. 3.0 x 18 mm stents tested using a simulated arterial model.
MAT-2006547 v6.0